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Phase I First-in-Human Study of Venetoclax in Patients With
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Soham Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu,
Franklin Peale, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse,
Gary B. Gordon, and John F. Gerecitano
A B S T R A C T
Purpose
B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma
(NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, phar-
macokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor.
Patients and Methods
A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until pro-
gressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation
and safety expansion cohorts. Treatment commenced with a 3-week dose ramp-up period for most
patients in dose-escalation cohorts and for all patients in safety expansion.
Results
NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29),
diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia
(Richter transformation; n = 7), Waldenström macroglobulinemia (n = 4), and marginal zone lym-
phoma (n = 3). Venetoclax was generally well tolerated. Clinical tumor lysis syndrome was not
observed, whereas laboratory tumor lysis syndrome was documented in three patients. Treatment-
emergent adverse events were reported in 103 patients (97%), a majority of which were grade 1 to
2 in severity. Grade 3 to 4 events were reported in 59 patients (56%), and the most common were
hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%). Overall
response rate was 44% (MCL, 75%; FL, 38%; DLBCL, 18%). Estimated median progression-free
survival was 6 months (MCL, 14 months; FL, 11 months; DLBCL, 1 month).
Conclusion
Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied
among NHL subtypes. We determined 1,200 mg to be the recommended single-agent dose for
future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable
response in MCL. Additional investigations including combination therapy to augment response
rates and durability are ongoing.
J Clin Oncol 35:826-833. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Dysregulation of apoptosis via overexpression
of the antiapoptotic protein B-cell leukemia/
lymphoma-2 (BCL-2) is fundamental to the bi-
ology of several subtypes of non-Hodgkin lym-
phoma (NHL). The BCL-2 gene was first cloned
in a lymphoid cell line1 and found to be a hall-
mark of the most common form of indolent
NHL, follicular lymphoma (FL).2,3 BCL-2 is
also overexpressed in approximately 30% of
diffuse large B-cell lymphomas (DLBCLs),4 and
amplification of chromosomal region 18q21
(which includes the BCL-2 locus) is frequently
found in mantle cell lymphoma (MCL).5
Venetoclax is a highly selective BCL-2 in-
hibitor with potent activity against FL, DLBCL,
and MCL cell lines, as well as in a t(14;18)-
carrying xenograft model.6 The M12-175 study
is a first-in-human dose-escalation trial of ven-
etoclax in patients with relapsed or refractory
chronic lymphocytic leukemia (CLL; arm A) or
NHL (arm B). The results in the CLL arm showed
a 79% response rate, including 20% of patients
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achieving complete remission.7 The potency of venetoclax in pa-
tients with CLLwas illustrated by the development of clinical tumor
lysis syndrome (TLS) in three of the initial 56 patients. Clinical TLS
is defined as occurrence of two or more metabolic abnormalities
during the same 24-hour period as well as an increased creatinine
level, cardiac dysrhythmia, seizure, or death.8 With adjustments to
the dose ramp-up schedule, there were no more clinical TLS events
in 60 additional patients with CLL enrolled. Venetoclax is now
approved by the US Food and Drug Administration for the treat-
ment of patients with CLLwith chromosome 17p deletion who have
received at least one prior therapy.9
Here, we report the results for the NHL cohort of theM12-175
study. The objectives were to define the safety profile, maximum-
tolerated dose (MTD), dose-limiting toxicities (DLTs), pharma-
cokinetics, and preliminary efficacy of venetoclax and determine
a recommended phase II dose and schedule for future NHL studies.
PATIENTS AND METHODS
Study Design
Arm B of the M12-175 study enrolled patients with relapsed or
refractory NHL between September 2011 and November 2014 and is
ongoing. The data cutoff for this publication was April 5, 2016. The trial
was conducted under the International Conference on Harmonisation
Good Clinical Practice guidelines and according to the Declaration of
Helsinki. A local institutional review or ethics board approved the study
at each site. All patients provided written informed consent before
participation.
Patient Eligibility
Detailed eligibility criteria are available in the protocol (Data Sup-
plement). Briefly, patients were required to have adequate bone marrow
function, an Eastern Cooperative Oncology Group performance status of
0 or 1, creatinine clearance$ 50 mL/min, liver transaminases # 3.03 the
upper limit of normal, and bilirubin # 1.53 the upper limit of normal.
One patient with multiple myeloma was enrolled early in the study, when
the inclusion criteria permitted patients with other lymphoproliferative
diseases. Patients were excluded if they had Burkitt or Burkitt-like lym-
phoma, lymphoblastic lymphoma or leukemia, post-transplantation
lymphoproliferative disorder, active infection, previous allogeneic stem-
cell transplantation (SCT) at any time, or autologous transplantation
within 6 months of starting therapy. Antilymphoma therapy was not
allowed within 14 days (8 weeks for monoclonal antibodies) before the first
dose. Corticosteroids were allowed for a limited duration for medical
indications other than antineoplastic intent.
Treatment
Venetoclax was administered orally once daily. Sequential dose-
escalation cohorts of $ three patients were accrued to a 3 + 3 design.10
Patients in the initial dose-escalation cohorts reached target daily doses of
200 to 1,200 mg. Safety expansion cohorts included only patients with FL
and DLBCL, who received a target dose of 1,200 mg daily. Patients
continued receiving daily venetoclax until progression of disease, un-
acceptable toxicity, or elective withdrawal in remission to proceed to al-
logeneic SCT. Growth factor support, supportive care, and antimicrobial
prophylaxis were provided according to institutional standards of care.
On the basis of the experience with CLL,7 an early amendment
implemented strict measures for TLS prophylaxis, monitoring, and
management (details provided in protocol; Data Supplement). Briefly,
patients were generally treated as outpatients (except for those with MCL
with maximum tumor diameter $ 10 cm, who received initial doses as
inpatients), with oral or intravenous hydration, allopurinol, and in some
cases rasburicase. Patients started at a low dose of venetoclax on day 1, with
subsequent intrapatient dose ramp-up (Appendix Table A1, online only). If
there was no evidence of TLS, patients received the next higher dose on day
2 or 8, with additional dose increases once per week until target dosing was
reached. Laboratory monitoring for TLS was performed at a minimum of 8
and 24 hours postdose at each dose increase.
Study Assessments
Safety. Adverse events (AEs) were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events
(version 4.0).11 The following events were reported as DLTs if they oc-
curred during the observation period of the lead-in plus the first 3 weeks at
target dosing and were thought to be at least possibly related to venetoclax:
grade 4 neutropenia$ 7 days (despite growth factor support), grade 3 to 4
neutropenia with fever, grade 4 thrombocytopenia, grade $ 2 bleeding
associated with thrombocytopenia, unexpected grade 2 toxicity that re-
quired dose modification or delay of $ 1 week, clinical TLS, or laboratory
TLS that did not resolve within 72 hours despite intervention. Venetoclax
could be reintroduced with dose reduction when a toxicity had improved
to grade # 1 or baseline if grade 2 at study entry.
Pharmacokinetics. Pharmacokinetic assessments were performed
predose and at 2, 3, 4, 6, 8, and 24 hours postdose, with additional
sampling 8 hours postdose on day 1 of weeks 2 to 5 if the patient was
increased to a higher dose.
Exploratory biomarkers. Formalin-fixed, paraffin-embedded tumor
samples were evaluated using immunohistochemistry (IHC) for BCL-2
(clone 124) and MYC (clone Y69) from Ventana Medical Systems (Tucson,
AZ). BCL-2 immunostaining was scored on a 0 to 3 intensity scale; samples
were coded BCL-2 high if$ 50% of lymphoma cells showed a cytoplasmic
intensity score of 2+ or 3+ and BCL-2 low if positive in , 50% of
lymphoma cells.12 Samples were coded MYC positive if $ 40% of lym-
phoma cells showed any level of MYC nuclear staining. DLBCL tumors
IHC positive for BCL-2 and MYC were classified as double-expressor (DE)
lymphoma.13 Classification of DLBCL tumor samples into activated B-cell
(ABC) or germinal center B-cell (GCB) subtypes was determined using the
Lymphoma Subtyping Test from NanoString Technologies (Seattle, WA).14
Efficacy. Efficacy end points included overall response rate (ORR),
progression-free survival (PFS), duration of response (DOR), time to
progression, and overall survival. Responses were assessed according to the
2007 International Working Group or the Fourth International Workshop
onWaldenströmMacroglobulinemia criteria.15,16 Computed tomography or
positron emission tomography with computed tomography was performed
at screening, weeks 6, 12 or 16, and 24, and every 12 weeks thereafter.
Patients were observed for survival after discontinuation of venetoclax.
Statistical Analysis
All patients who received at least one dose of venetoclax were in-
cluded in the safety, pharmacokinetics, and survival analyses. Descriptive
statistics including medians, standard deviations, and ranges were cal-
culated. The Kaplan-Meier method was used for time-to-event analyses.
PFS and DOR data were censored at the time of last tumor assessment in
patients who did not experience an event or at time of data cutoff if an
assessment was performed after the cutoff. Data were analyzed both by
specific dose cohort and by pooling multiple cohorts. Pharmacokinetic
parameters were assessed using a noncompartmental approach and bio-
marker studies by descriptive statistics.
RESULTS
Patient Demographic and Clinical Characteristics
A total of 106 patients with a median age of 66 years (range,
25 to 86 years) were enrolled. Key demographic and clinical
jco.org © 2017 by American Society of Clinical Oncology 827
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characteristics are summarized in Table 1. Seventy patients were
treated in dose-escalation cohorts (target daily dose, 200 to 1,200mg).
Thirty-six patients (DLBCL, n = 21; FL, n = 15) were treated in the
safety expansion cohort (target daily dose, 1,200 mg). The median
number of prior therapies was three (range, one to 10). Among
patients with MCL, none had received ibrutinib or lenalidomide, and
five had received prior bortezomib-based therapy. Fifteen patients
had received granulocyte colony-stimulating factor (G-CSF) within
6 months of study entry. Approximately half of the patients had bulky
lymphadenopathy (. 5 cm, 45%; . 10 cm, 13%) at study entry.
Safety Profile and Disposition
The mean duration of venetoclax treatment was 5.3 months
(range, 0.2 to 46.0 months). The MTD of venetoclax was not
reached. Two DLTs occurred, both in the 600-mg dose-escalation
cohort: one grade 4 neutropenia in a patient with Richter trans-
formation DLBCL (DLBCL-RT) that resolved after pegfilgrastim
and a 9-day study drug interruption, and one grade 3 febrile
neutropenia in a patient with DLBCL that resolved after a 2-day
study drug interruption and G-CSF. Amajority of AEs were grade 1
to 2 in severity; grade 3 to 4 events were reported in 59 patients
(56%) and were independent of dose (Table 2). Grade 3 to 4
hematologic toxicities included anemia (15%), neutropenia (11%),
and thrombocytopenia (9%). Serious AEs that occurred in . 2%
of patients included hyponatremia, influenza, and lower re-
spiratory tract infection (3% each; Table 2). There was no cu-
mulative toxicity apparent with prolonged dosing and no clear
association of toxicity with venetoclax dose. Fifteen patients re-
quired dose reductions, including nine of the 51 patients treated at
1,200 mg (five for nausea, four for diarrhea). Seventeen patients
(16%) required G-CSF support (eight received filgrastim, seven
pegfilgrastim, and two both at different times). Twenty-two total
G-CSF doses were administered in 13 patients. Eight events of
neutropenia prompted dose interruption, and five events
prompted dose reduction. Only two patients received prolonged
G-CSF support.
Eighty-seven patients have ended study participation: 77 had
progressive disease, three had AEs (anemia, diarrhea and nausea,
toxic myopathy), three underwent allogeneic SCT while in re-
mission, two withdrew consent, one was noncompliant with the
protocol, and one was removed at investigator discretion. Thirty-
eight deaths have occurred: 10 within 30 days of venetoclax dis-
continuation (all related to disease progression) and 28 $ 30 days
after discontinuation (of which 24 were the result of disease
progression).
Given the TLS observed in CLL,7 there was particular vigilance
for this potential toxicity. Clinical TLS was not observed in the
NHL population. Three patients with bulky disease (maximal
lymph node diameter, . 10 cm) had laboratory changes meeting
Cairo-Bishop criteria for laboratory TLS17 within 24 hours of
initial dosing. All three patients received TLS treatment and
continued venetoclax as scheduled without dose interruption.
Pharmacokinetics
Venetoclax pharmacokinetics in patients with NHL (Ap-
pendix Fig A1, online only) were similar to those in patients with
CLL.7 Plasma concentrations peaked approximately 6 to 8 hours
after dosing, and the terminal half-life was approximately 16 hours.
No trend was observed in dose-normalized steady-state trough
levels over time.
Preliminary Efficacy
Of the total 106 patients enrolled, 44% achieved an objective
response (complete response [CR] or partial response [PR]). Best
response according to histology is summarized in Table 3. Re-
sponses were seen in all histologies, with the highest response rate
in MCL (ORR, 75% [CR, 21%]). Significant antitumor activity was
also observed in other histologies, including FL (ORR, 38% [CR,
14%]), DLBCL (ORR, 18% [CR, 12%]), DLBCL-RT (ORR, 43%
[no CRs]), marginal zone lymphoma (MZL; ORR, 67% [no CRs]),
and Waldenström macroglobulinemia (WM; ORR, 100% [no
CRs]). The median time to first response for all responders was
Table 1. Patient Demographic and Clinical Characteristics (N = 106)
Characteristic
No. (%)
All Patients MCL (n = 28) FL (n = 29) DLBCL* (n = 34) DLBCL-RT (n = 7) WM (n = 4) MZL (n = 3) Other† (n = 1)
Age (years)
Median 66 72 64 67 73 67 63 56
Range 25-86 35-85 46-75 25-86 57-77 58-73 63-67 56-56
Previous therapies
Median 3 3 3 3 3 4 4 2
Range 1-10 1-7 1-10 1-8 2-7 3-5 2-6 2-2
Prior ASCT 16 7 2 6 0 1 0 0
Bulky nodes (cm)
. 5 48 (45) 14 (50) 8 (28) 17 (50) 5 (71) 2 (50) 0 1 (100)
. 10 14 (13) 3 (11) 2 (7) 6 (18) 2 (29) 2 (50) 0 0
LDH . upper limit of normal 45 (42) 7 (25) 10 (34) 20 (59) 7 (100) 0 0 1 (100)
High BCL-2 expression‡ 41 of 46 13 of 14 14 of 15 9 of 12 1 of 1 3 of 3 1 of 1 0
Abbreviations: ASCT, autologous stem-cell transplantation; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LDH, lactate dehydrogenase; MCL, mantle
cell lymphoma; MZL, marginal zone lymphoma; RT, Richter transformation; WM, Waldenström macroglobulinemia.
*Includes patients with primary mediastinal B-cell lymphoma (n = 2).
†One patient with multiple myeloma (a histology allowed before an early study amendment) had early disease progression and discontinued study after 21 days.
‡Proportion of patients with high B-cell leukemia/lymphoma-2 expression by immunohistochemistry (. 50% lymphoma cells scored 2+ or 3+) among those with
adequate samples for analysis.
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42 days (range, 30 to 366 days; MZL, 36.5; MCL, 38; DLBCL,
39; FL, 40; WM, 74.5; DLBCL-RT, 100 days). The depth of
nodal response across different histologies is shown in
Figure 1A. For MCL, objective responses were seen even at
doses# 800 mg (ORR, 76%, including CR rate of 24%) and not
at a higher rate at doses higher than this (Fig 1B). For DLBCL,
responses were observed across dose cohorts, but a specific
dose threshold for efficacy was not identified (Fig 1C). In
FL, objective responses were more frequent at higher doses
(. 600 mg), particularly at the 1,200-mg dose (nodal re-
sponses, 44%; Fig 1D).
The estimated median PFS for all 106 patients was 6 months
(95% CI, 4 to 10), but it varied by histology; for patients with
MCL, FL, and DLBCL, it was 14, 11, and 1 months, respectively
(Fig 2A). DOR for the four patients withWMwas 11.1, 12.4, 38.2,
and 41.5 months, and for the two patients with MZL, it was 2.3
and 23.6 months, respectively. The estimated 12-month overall
survival for all patients was 70%, and it was 100%, 82%, and 32%
for those with FL, MCL, and DLBCL, respectively (Fig 2B).
Patients with MCL or FL who achieved CRs had more durable
responses than those who achieved PRs as best response (Figs 2C
and 2D). Three patients with chemotherapy-refractory disease,
Table 2. Adverse Events and Serious Adverse Events Reported in Study Patients
Adverse Event


















Any event 103 (97) 21 (96) 33 (100) 49 (96) 59 (56) 14 (64) 21 (64) 24 (47)
Nausea 51 (48) 9 (41) 15 (45) 27 (53) 0 0 0 0
Diarrhea 48 (45) 7 (32) 14 (42) 27 (53) 3 (3) 0 2 (6) 1 (2)
Fatigue 44 (42) 10 (45) 9 (27) 25 (49) 7 (7) 2 (9) 2 (6) 3 (6)
Decreased
appetite
23 (22) 4 (18) 4 (12) 15 (29) 1 (1) 0 0 1 (2)
Vomiting 23 (22) 5 (23) 6 (18) 12 (24) 0 0 0 0
Constipation 22 (21) 6 (27) 7 (21) 9 (18) 2 (2) 1 (5) 1 (3) 0
Headache 19 (18) 2 (9) 7 (21) 10 (20) 0 0 0 0
Anemia 18 (17) 7 (32) 6 (18) 5 (10) 16 (15) 7 (32) 5 (15) 4 (8)
Cough 18 (17) 7 (32) 6 (18) 5 (10) 1 (1) 1 (5) 0 0
Neutropenia 18 (17) 4 (18) 8 (24) 6 (12) 12 (11) 3 (14) 5 (15) 4 (8)
Back pain 17 (16) 3 (14) 6 (18) 8 (16) 1 (1) 0 0 1 (2)
Upper RTI 17 (16) 5 (23) 8 (24) 4 (8) 1 (1) 1 (5) 0 0
Serious†
Any serious event 27 (25)
Hyponatremia 3 (3)
Influenza 3 (3)
Lower RTI 3 (3)
Dehydration 2 (2)
Diarrhea 2 (2)
Febrile neutropenia 2 (2)
Hypotension 2 (2)
Pleural effusion 2 (2)
Viral infection 2 (2)
Viral RTI 2 (2)
Abbreviation: RTI, respiratory tract infection.
*Emergent adverse events reported in $ 15% of the patients.
†Serious adverse events reported in at least two patients; excludes disease progression.

















Overall response 47 (44) 21 (75) 11 (38) 6 (18) 3 (43) 4 (100) 2 (67)
CR 14 (13) 6 (21) 4 (14) 4 (12) 0 0 0
PR 33 (31) 15 (54) 7 (24) 2 (6) 3 (43) 4 (100) 2 (67)
SD 32 (30) 5 (18) 17 (59) 8 (24) 2 (29) 0 0
PD 24 (23) 2 (7) 1 (3) 19 (56) 1 (14) 0 1 (33)
Abbreviations: CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma;
PD, progressive disease; PR, partial response; RT, Richter transformation; SD, stable disease; WM, Waldenström macroglobulinemia.
*Two patients with DLBCL and DLBCL-RT had no response data, and the patient with multiple myeloma with PD is not included in the table.
†Includes patients with primary mediastinal B-cell lymphoma (n = 2).
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including DLBCL, primary mediastinal large B-cell lymphoma,
and MCL, proceeded to allogeneic SCTafter achieving remission
with venetoclax (CR, PR, and PR, respectively); all three patients
remained disease free without further treatment at 24.5, 24.5,
and 22.7 months, respectively, after transplantation during the
protocol-defined follow-up period of 2 years after venetoclax
discontinuation. At the time of data cutoff, 19 patients con-
tinued to receive study treatment and derive clinical benefit
(Fig 3).
Exploratory Biomarkers
Baseline tissue was available from 46 patients; 41 samples
(89%) were BCL-2 high by IHC. BCL-2 expression according to
histology is summarized in Table 1. High expression was observed
in all histologies, includingMCL (13 [93%] of 14), FL (14 [93%] of
15), DLBCL (nine [75%] of 12), and WM (three [100%] of three),
but did not correspond to observed responses. The ORR was
similar in patients with BCL-2 low and BCL-2 high expression
based on IHC staining (Appendix Table A2, online only). Cell-of-
origin molecular subtype was determined for the five baseline
DLBCL tumor samples that were available. Four patients had
a GCB subtype, and one patient had an ABC subtype. CRs were
observed in one patient each with ABC and GCB subtypes
(Appendix Table A3, online only). BCL-2 and MYC DE lym-
phoma was observed in four of six evaluable DLBCL tumors. Two
patients with DE lymphoma achieved an objective response (CR,
n = 1; PR, n = 1; Appendix Table A4, online only). All five patients
with DLBCL with sufficient tissue for fluorescent in situ hy-
bridization analysis were negative for BCL-2 and MYC rear-
rangements. Two other patients had double-hit DLBCL noted in
prior pathology reports, and neither patient achieved a response
to venetoclax.
DISCUSSION
Venetoclax was well tolerated in patients with relapsed or re-





















































































































Dose (mg) Dose (mg)
Fig 1. Venetoclax induces response in several non-Hodgkin lymphoma histologies. (A) Waterfall plot depicting the best percentage change in the sum of the product of
the diameters of target lymph nodes in patientswith evaluable disease. Objective response by target dose level in patients with (B) mantle cell lymphoma (MCL), (C) diffuse
large B-cell lymphoma (DLBCL), and (D) follicular lymphoma (FL). CR, complete response; MZL, marginal zone lymphoma; PD, progressive disease; PR, partial response;
RT, Richter transformation; SD, stable disease; WM, Waldenström macroglobulinemia.
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led to enhanced antilymphoma activity without the dose-limiting
thrombocytopenia observed with its predecessor navitoclax,18
a less selective BH3 mimetic. No clinical TLS was observed with
starting doses of up to 400 mg daily (the dose now being used for
studies of venetoclax in patients with CLL) or with ongoing
dosing at 1,200 mg daily. Only three patients with high tumor
burden had evidence of laboratory TLS, and all were managed
successfully with intravenous fluids, corrective measures, and
continuation of allopurinol. These results suggest that for NHL
subtypes other than MCL, a dosing strategy starting at 400 mg
daily for 1 week followed by weekly ramp-up from 800 mg daily
to 1,200 mg daily thereafter with outpatient monitoring for TLS
is well tolerated. Patients with high tumor burden, particularly
those with MCL, are at increased risk for TLS and may be best
managed with a more conservative dosing strategy, including
a starting dose of 100 mg daily for 1 week, followed by weekly
ramp-up to 200, 400, and 800 mg daily.
The other toxicities of venetoclax were mild and includedmostly
low-grade GI toxicity and neutropenia. The latter is likely an on-
target effect of BCL-2 inhibition in neutrophil precursors19 and
was well managed with supportive care including growth factor
support administered concomitantly with treatment or dose
interruption. Because a. 30% DLTrate was not seen at any dose
level tested, no formal MTD was determined. The recommended
phase II dose was therefore determined by the investigators to be
the maximum cleared dose for FL and DLBCL (1,200 mg) and for
DLBCL-RT (600 mg). For MCL, 800 mg was chosen given the
significant activity observed at this dose and the risk of in-
cremental toxicity at higher doses.
Venetoclax demonstrated significant single-agent activity
across a broad range of NHL subtypes. The highest response
rate was seen in MCL, with 75% of patients achieving re-
sponses, including 21% achieving CRs. Patients with MCL
had a median PFS of 14 months, with only one progression to
date among six complete responders and some patients re-
ceiving treatment . 33 months. These results are similar
to those seen in MCL with the Bruton tyrosine kinase in-
hibitor ibrutinib (ORR, 68% [CR, 21%]; median PFS,
13.9 months).20
Patients with FL had a 38% response rate, with 14% achieving
CRs, and a median PFS of 11 months, similar to the results seen
with the delta isoform–specific phosphatidylinositol-3-kinase
inhibitor idelalisib in FL (ORR, 47% to 57%; PFS, 7.6 to
11 months).21,22 Higher response rates were seen with higher doses
of venetoclax in FL; the ORR was 44% for the 18 patients treated at
1,200 mg compared with an ORR of 27% for the 11 patients treated
at# 900mg. These preliminary results need to be explored further in
additional studies.
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Time (months)Time (months)
CR (n = 6)
PR (n = 15)
CR (n = 4)
PR (n = 7)
No. of patients
No. of patients No. of patients
No. of patients
Fig 2. Durability of antitumor activity of
venetoclax. Dashed lines indicate the 50%
mark in each panel. (A) Progression-free
survival (PFS) of patients with mantle cell
lymphoma (MCL), follicular lymphoma (FL),
and diffuse large B-cell lymphoma (DLBCL).
Of note, three patients with previously
chemotherapy-refractory disease, including
DLBCL, primary mediastinal large B-cell lym-
phoma, and MCL, who proceeded to alloge-
neic stem-cell transplantation after achieving
remission with venetoclax were censored
when they left the study but remained dis-
ease free during the protocol-defined 2-year
follow-up period after venetoclax therapy. (B)
Overall survival (OS) of patients with MCL,
FL, and DLBCL. Duration of response in (C)
evaluable patients with MCL and (D) patients
with FL who achieved a complete (CR) or
partial response (PR).
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The response rate for patients with DLBCL was 18%, and
unlike in FL, it did not seem to vary based on cohort dose.
Nevertheless, four patients achieved CRs, including two patients
who went on to undergo allogeneic SCT and remain in complete
remission now . 2 years after transplantation. B-cell receptor
pathway antagonists have shown limited efficacy in DLBCL, and
therefore, novel agents such as venetoclax are urgently needed for
combination regimens. Cell-of-origin data were only available in
five patients with DLBCL, which is a limitation of this study.
Significant responses to venetoclax were also noted in patients with
MZL and WM, supporting the exploration of venetoclax in future
studies in these diseases.
Understanding the heterogeneity of clinical responses ob-
served will require further exploration. In the CLL arm, the depth
of initial response to venetoclax was associated with the level of
mitochondrial priming for apoptosis as determined by the BH3
profiling assay.23 Correlative samples were limited in the NHL arm
and did not allow for systematic evaluation of parameters such as
antiapoptotic family protein or mRNA expression, mutational
analysis, or BH3 profiling. Exploratory analysis of the level of BCL-2
expression by IHC showed no significant association with clinical
response or TLS risk in this patient group, where all patient samples
tested had some BCL-2 expression. These results indicate that BCL-2
protein expression alone is not an adequate biomarker to predict
clinical response or TLS risk, and functional assessments of the
relative balance of the anti- and proapoptotic BCL-2 family proteins
should be explored as biomarkers. Additional biomarker in-
vestigations will be important in future studies of venetoclax in
NHL.
The optimal combination partners for venetoclax in NHL
remain to be defined, and studies are under way to assess the safety
and efficacy of combining venetoclax with chemotherapy,
monoclonal antibodies, and B-cell receptor signaling inhibitors.
Preclinical data suggest that abbreviated venetoclax use in com-
binationwith DNA-damaging cytotoxic therapies may be sufficient
to achieve durable remissions.6,19,24 Combination with rituximab
augmented the efficacy of the less selective BCL-2 inhibitor
navitoclax in FL,25 and similar studies with venetoclax are ongoing.
We conclude that venetoclax is active as a single agent in NHL,
with clinical benefit varying depending on histologic subtype.
Targeted inhibition of BCL-2 will likely have a greater clinical impact
when venetoclax is combined with other agents. The favorable
toxicity profile and unique mechanism of action suggest that ven-
etoclax will be a logical partner in a range of combination regimens.
Ongoing trials will define the optimal use of venetoclax in NHL.
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Fig 3. Patient status during study by his-
tology, including mantle cell lymphoma
(MCL), follicular lymphoma (FL), diffuse
large B-cell lymphoma (DLBCL), DLBCLwith
Richter transformation (RT), Waldenström
macroglobulinemia (WM), and marginal
zone lymphoma (MZL). Right arrows indi-
cate patients who continue to receive active
treatment.
832 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Davids et al
REFERENCES
1. Pegoraro L, Palumbo A, Erikson J, et al: A 14;
18 and an 8;14 chromosome translocation in a cell
line derived from an acute B-cell leukemia. Proc Natl
Acad Sci USA 81:7166-7170, 1984
2. McDonnell TJ, Deane N, Platt FM, et al: Bcl-2-
immunoglobulin transgenic mice demonstrate ex-
tended B cell survival and follicular lymphoprolifera-
tion. Cell 57:79-88, 1989
3. Tsujimoto Y, Finger LR, Yunis J, et al: Cloning
of the chromosome breakpoint of neoplastic B cells
with the t(14;18) chromosome translocation. Science
226:1097-1099, 1984
4. Huang JZ, Sanger WG, Greiner TC, et al: The
t(14;18) defines a unique subset of diffuse large
B-cell lymphoma with a germinal center B-cell
gene expression profile. Blood 99:2285-2290,
2002
5. Bentz M, Plesch A, Bullinger L, et al: t(11;14)-
positive mantle cell lymphomas exhibit complex
karyotypes and share similarities with B-cell chronic
lymphocytic leukemia. Genes Chromosomes Cancer
27:285-294, 2000
6. Souers AJ, Leverson JD, Boghaert ER, et al:
ABT-199, a potent and selective BCL-2 inhibitor,
achieves antitumor activity while sparing platelets.
Nat Med 19:202-208, 2013
7. Roberts AW, Davids MS, Pagel JM, et al:
Targeting BCL2 with venetoclax in relapsed chronic
lymphocytic leukemia. N Engl J Med 374:311-322,
2016
8. Howard SC, Jones DP, Pui CH: The tumor lysis
syndrome. N Engl J Med 364:1844-1854, 2011
9. AbbVie: Venclexta (venetoclax) tablets: Pre-
scribing information. http://www.rxabbvie.com/pdf/
venclexta.pdf
10. Le Tourneau C, Lee JJ, Siu LL: Dose escala-
tion methods in phase I cancer clinical trials. J Natl
Cancer Inst 101:708-720, 2009
11. National Institutes of Health, National Cancer
Institute: Common Terminology Criteria for Adverse
Events (CTCAE), Version 4.03. https://ctep.cancer.
gov/protocolDevelopment/electronic_applications/
ctc.htm
12. Punnoose EA, Leverson JD, Peale F, et al:
Expression profile of BCL-2, BCL-XL, and MCL-1
predicts pharmacological response to the BCL-2
selective antagonist venetoclax in multiple mye-
loma models. Mol Cancer Ther 15:1132-1144, 2016
13. Johnson NA, Slack GW, Savage KJ, et al:
Concurrent expression of MYC and BCL2 in diffuse
large B-cell lymphoma treated with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and
prednisone. J Clin Oncol 30:3452-3459, 2012
14. Scott DW, Wright GW, Williams PM, et al:
Determining cell-of-origin subtypes of diffuse large
B-cell lymphoma using gene expression in formalin-
fixed paraffin-embedded tissue. Blood 123:1214-1217,
2014
15. Cheson BD, Pfistner B, Juweid ME, et al:
Revised response criteria for malignant lymphoma.
J Clin Oncol 25:579-586, 2007
16. Dimopoulos MA, Gertz MA, Kastritis E, et al:
Update on treatment recommendations from the
Fourth International Workshop on Waldenstrom’s
Macroglobulinemia. J Clin Oncol 27:120-126, 2009
17. Cairo MS, Bishop M: Tumour lysis syndrome:
New therapeutic strategies and classification. Br J
Haematol 127:3-11, 2004
18. Wilson WH, O’Connor OA, Czuczman MS,
et al: Navitoclax, a targeted high-affinity inhibitor of
BCL-2, in lymphoid malignancies: A phase 1 dose-
escalation study of safety, pharmacokinetics, phar-
macodynamics, and antitumour activity. Lancet
Oncol 11:1149-1159, 2010
19. Leverson JD, Phillips DC, Mitten MJ, et al:
Exploiting selective BCL-2 family inhibitors to dissect
cell survival dependencies and define improved
strategies for cancer therapy. Sci Transl Med 7:
279ra40, 2015
20. Wang ML, Rule S, Martin P, et al: Targeting
BTKwith ibrutinib in relapsed or refractorymantle-cell
lymphoma. N Engl J Med 369:507-516, 2013
21. Flinn IW, Kahl BS, Leonard JP, et al: Idelalisib,
a selective inhibitor of phosphatidylinositol 3-kinase-d,
as therapy for previously treated indolent non-Hodgkin
lymphoma. Blood 123:3406-3413, 2014
22. Gopal AK, Kahl BS, de Vos S, et al: PI3Kd in-
hibition by idelalisib in patients with relapsed indolent
lymphoma. N Engl J Med 370:1008-1018, 2014
23. Anderson MA, Deng J, Seymour JF, et al: The
BCL2 selective inhibitor venetoclax induces rapid
onset apoptosis of CLL cells in patients via a TP53-
independent mechanism. Blood 127:3215-3224,
2016
24. Mason KD, Vandenberg CJ, Scott CL, et al: In
vivo efficacy of the Bcl-2 antagonist ABT-737 against
aggressive Myc-driven lymphomas. Proc Natl Acad
Sci USA 105:17961-17966, 2008
25. Roberts AW, Advani RH, Kahl BS, et al: Phase
1 study of the safety, pharmacokinetics, and anti-
tumour activity of the BCL2 inhibitor navitoclax in
combination with rituximab in patients with relapsed
or refractory CD20+ lymphoid malignancies. Br J
Haematol 170:669-678, 2015
Affiliations
Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson,
University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical
Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer
Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD
Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California
San Diego, San Diego, CA; Ahmed Hamed Salem,Martin Dunbar,Ming Zhu, Jeremy A. Ross, Lori Gressick,Monali Desai, Su Young
Kim,Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy,
Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering
Cancer Center and Weill Cornell Medical Center, New York, NY.
Support
Supported by AbbVie (which also funded editorial support) and Genentech; in part by the National Institutes of Health/National
Cancer Institute Cancer Center Support Grant No. P30 CA008748 (J.F.G.); and in part by a Career Development Award from the American
Society of Clinical Oncology (M.S.D.).
Prior Presentation
Presented in part at the 57th Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, December 5-8, 2015; Pan
Pacific Lymphoma Conference, Kohala Coast, HI, July 21-25, 2014; 19th Congress of the European Hematology Association (EHA), Milan,
Italy, June 12-15, 2014; 50th AnnualMeeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, May 30-June 3, 2014; 55th
ASH Annual Meeting, New Orleans, LA, December 7-10, 2013; 18th EHA Congress, Stockholm, Sweden, June 13-16, 2013; 49th ASCO
Annual Meeting, Chicago, IL, May 31-June 4, 2013; 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June
19-22, 2013; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012.
n n n
jco.org © 2017 by American Society of Clinical Oncology 833
Venetoclax Monotherapy in Patients With NHL
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Matthew S. Davids
Consulting or Advisory Role: Infinity Pharmaceuticals, Genentech,
Gilead Sciences, Janssen Pharmaceuticals, Pharmacyclics, TG
Therapeutics, Celgene, AbbVie
Research Funding: Genentech (Inst), TG Therapeutics (Inst), Infinity
Pharmaceuticals (Inst), Pharmacyclics (Inst), AbbVie (Inst)
Andrew W. Roberts
Research Funding: AbbVie (Inst), Genentech (Inst), Amgen (Inst),
BeiGene (Inst), Servier Laboratories (Inst)
Patents, Royalties, Other Intellectual Property: Employee of Walter and
Eliza Hall Institute, which receives milestone and royalty payments related
to venetoclax (Inst)
John F. Seymour
Consulting or Advisory Role: Roche, Genentech
Speakers’ Bureau: Roche, Genentech
Research Funding: AbbVie, Genentech
John M. Pagel
Consulting or Advisory Role: Pharmacyclics, Gilead Sciences
Brad S. Kahl
Consulting or Advisory Role: AbbVie, Celgene, Genentech, Millennium,
Pharmacyclics, Seattle Genetics
Research Funding: AbbVie, Genentech
William G. Wierda
Consulting or Advisory Role: Sanofi, Genentech, Pharmacyclics, Celgene,
Gilead Sciences, GlaxoSmithKline, Novartis, Genzyme, Merck, AbbVie,
Emergent BioSolutions
Research Funding: GlaxoSmithKline, Novartis, AbbVie, Genentech,
Karyopharm Therapeutics, Pharmacyclics, Acerta Pharma, Gilead
Sciences, Janssen Pharmaceuticals, Emergent BioSolutions, Juno
Therapeutics, Kite Pharma
Soham Puvvada
Consulting or Advisory Role: AbbVie, Genentech, Pharmacyclics, Seattle
Genetics
Speakers’ Bureau: Gilead Sciences
Research Funding: Spectrum Pharmaceuticals (Inst), AbbVie (Inst),
Genentech (Inst), Seattle Genetics (Inst), Takeda Pharmaceuticals (Inst),
Janssen Pharmaceuticals (Inst)
Thomas J. Kipps





Research Funding: AbbVie (Inst), Genentech (Inst)
Travel, Accommodations, Expenses: AbbVie
Ahmed Hamed Salem
Employment: AbbVie
Stock or Other Ownership: AbbVie
Martin Dunbar
Employment: AbbVie
Stock or Other Ownership: AbbVie
Ming Zhu
Employment: AbbVie
Stock or Other Ownership: AbbVie
Franklin Peale
Employment: Genentech
Stock or Other Ownership: Genentech
Jeremy A. Ross
Employment: AbbVie
Stock or Other Ownership: AbbVie
Lori Gressick
Employment: AbbVie
Stock or Other Ownership: AbbVie
Monali Desai
Employment: AbbVie
Stock or Other Ownership: AbbVie
Travel, Accommodations, Expenses: AbbVie
Su Young Kim
Employment: AbbVie
Stock or Other Ownership: AbbVie
Maria Verdugo
Employment: AbbVie
Stock or Other Ownership: AbbVie
Rod A. Humerickhouse
Employment: AbbVie
Stock or Other Ownership: AbbVie
Gary B. Gordon
Employment: AbbVie, Abbott Laboratories, Medtronic
Stock or Other Ownership: AbbVie
John F. Gerecitano
Honoraria: Genentech, AbbVie, Bayer HealthCare Pharmaceuticals,
Gilead Sciences, Samus Therapeutics
Consulting or Advisory Role: Genentech, AbbVie, Bayer HealthCare
Pharmaceuticals, Gilead Sciences, Samus Therapeutics
© 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Davids et al
Acknowledgment
We thank the patients and their families, study coordinators, and support staff. Editorial support was provided by Sharanya Ford, of
AbbVie, and by Evidence Scientific Solutions (Philadelphia, PA) and funded by AbbVie. Data programming and analysis support was
provided by Joseph Beason.
Appendix
Table A1. Intrapatient Ramp-Up Scheme in Arm B of the M12-175 Study








B7a MCL 7 20-50-100-200-400
B7b NHL 4 300-600-900
B8a MCL 7 20-50-100-200-400-800
B8b NHL 9 400-800-1,200
B8c DLBCL-RT 5 20-50-100-200-400
B9a MCL 6 100-200-400-800-1,200
Safety expansion
FL and de novo DLBCL 36 400-800-1,200
NOTE. Patients in each dose-escalation cohort and the safety expansion cohort
were started at the lowest dose and escalated to the target dose (indicated by
bold font). In cohort B6, TLS events that occurred in the CLL arm of this study led
to a modified, more gradual dose ramp-up schedule. Patients with MCL were
expected to show similarity to patients with CLL, and thus, their ramp-up
schedulemimicked that for CLL, and beginning with cohort B7, patients followed
one of two ramp-up schedules. Similarly, patients with RT followed a ramp-up
scheme identical to that for patients with CLL. Two patients with DLBCL-RT
were previously enrolled in cohort B5, which had a maximum dose of 600 mg,
and five patientswith DLBCL-RTwere enrolled in cohort B8c, which followed the
revised CLL dosing schedule, with a maximum dose of 400 mg.
Abbreviations: CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell
lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; NHL, non-
Hodgkin lymphoma (including marginal zone lymphoma and Waldenström
macroglobulinemia); RT, Richter transformation; TLS, tumor lysis syndrome.
*One patient in cohort B6 had MCL; this patient started with a lower dose of
200 mg and then ramped up to 400 and then 800 mg.
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Table A2. Summary of Objective Responses and PFS by BCL-2 Expression Data (n = 46)
BCL-2 Expression Status* Total Patients
Best Response
ORR (%)† Mean PFS (months)CR PR
Low (1+) 5 2 0 40 9
High ($ 2+) 41 6 13 46 11
2+ 12 1 4 42 9
3+ 29 5 9 48 12
Abbreviations: BCL-2, B-cell leukemia/lymphoma-2; CR, complete response; IHC, immunohistochemistry; ORR, overall response rate; PFS, progression-free survival;
PR, partial response.
*BCL-2 stainingwas scored on a 0 to 3 intensity scale, and sampleswere coded BCL-2 high if$ 50%of tumor cells showed a cytoplasmic intensity score of 2+ or 3+. An
IHC score of 2+ was assigned if lymphoma cells had a staining intensity equal to the predominant intensity of cytoplasmic staining in the mantle zone B cells and
paracortical T cells found in tonsils, which served as positive control tissue. Specimens with a signal weaker or stronger than 2+ were assigned an intensity of 1+ or 3+,
respectively. Sampleswith an intensity of 1+were coded as BCL-2 low; no tissue sample had an IHC intensity score of 0 among the 46 patientswith samples for analysis.
†Percentage of patients achieving either CR or PR.
Table A3. Objective Responses by DLBCL COO Subtype
Patient Histology LST Linear Predictor Score COO Subtype Best Objective Response
1 DLBCL ‒69.4 GCB PD
2 DLBCL 2,895.2 ABC CR
3 DLBCL 819.9 GCB SD
4 DLBCL 1,042 GCB SD
5 DLBCL 1,214 GCB CR
Abbreviations: ABC, activated B cell; COO, cell of origin; CR, complete response; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell; LST, lymphoma
subtype test; PD, progressive disease; SD, stable disease.
Table A4. Objective Responses by BCL-2 and MYC DE Subtype
Patient Histology
IHC
Subtype Best Objective ResponseBCL-2* MYC (%)†
1 DLBCL-RT 3+ 40 DE PR
2 DLBCL 3+ 100 DE PD
3 DLBCL 3+ 80 DE PD
4 DLBCL 3+ 90 DE CR
5 DLBCL 3+ 30 Non-DE SD
6 DLBCL 1+ 20 Non-DE PD
Abbreviations: BCL-2, B-cell leukemia/lymphoma-2; CR, complete response; DE, double expressor; DLBCL, diffuse large B-cell lymphoma; IHC, immunohisto-
chemistry; PD, progressive disease; PR, partial response; RT, Richter transformation; SD, stable disease.
*BCL-2 stainingwas scored on a 0 to 3 intensity scale, and sampleswere coded BCL-2 high if$ 50%of tumor cells showed a cytoplasmic intensity score of 2+ or 3+. An
IHC score of 2+ was assigned if lymphoma cells had a staining intensity equal to the predominant intensity of cytoplasmic staining in the mantle zone B cells and
paracortical T cells found in tonsils, which served as positive control tissue. Specimens with a signal weaker or stronger than the latter 2+ score were assigned an
intensity of 1+ or 3+, respectively.
†Samples were coded MYC positive if $ 40% of tumor cells showed any level of MYC nuclear staining above background.
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Fig A1. Mean venetoclax plasma concentration. Time profiles in (A, B) dose-escalation and (C, D) safety expansion cohorts according to (A, C) linear and (B, D) log-linear
scales. Error bars represent standard deviations.
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